Send us a text

This episode focus on the RNA interference (RNAi) therapeutics market, highlighting both the broader industry landscape and a major strategic collaboration. One source provides an overview of eight leading RNAi therapeutics companies, such as Alnylam and Roche, detailing their proprietary delivery platforms and competitive positions in treating various diseases. The remaining sources all report on a significant agreement between Eli Lilly and SanegeneBio, where Lilly is investing up to $1.2 billion to license SanegeneBio's proprietary LEAD™ platform for developing novel RNAi candidates specifically targeting metabolic disorders. This partnership validates the potential of SanegeneBio's tissue-selective delivery technology, while positioning Eli Lilly to accelerate the clinical development and commercialization of these next-generation therapies.

Disclaimer: This podcast by kavout.com is for informational and educational purposes only and does not constitute investment advice. All opinions are those of the hosts and guests. Please consult a qualified financial advisor before making any investment decisions.